REMARV — 1402948
Application number
1402948
Type(s)
Word
Category
Trademark
CIPO Status
ABANDONED SECTION 40(3)
TM5 status
DEAD/APPLICATION/
Withdrawn/Abandoned
The owner of the trademark application withdrew (e.g. abandoned) the application and the application is no longer active.
Filed
2008-07-11
Applicant
Glaxo Group Limited
980 Great West Road
Brentford, Middlesex
England TW8 9GS
UNITED KINGDOM
Agent
GOWLING WLG (CANADA) LLP
SUITE 2600, 160 ELGIN STREET
OTTAWA
ONTARIO K1P1C3
Documents
Index headings
- REMARV
Goods (Nice class & Statement)
- (1) Pharmaceutical preparations for use as anti-infectives; Pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), HPV, RSV, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; Pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, diabetes, metabolic syndrome, obesity, weight loss and weight management; Pharmaceutical preparations for the treatment or prevention of cardiovascular, cardiopulmonary, cardio-renal, and renal diseases; Pharmaceutical preparations for the prevention and treatment of oncological diseases; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for the treatment and prevention of respiratory diseases and their symptoms; Pharmaceutical preparations for the treatment of central nervous system diseases and disorders namely: central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, depression and anxiety and their related disorders namely schizophrenia and psychoses; Pharmaceutical preparations for the treatment of Parkinson's Disease, Alzheimers disease and dementia; Pharmaceutical preparations for the treatment of insomnia, restless leg, fibromyalgia, epilepsy, migraine, pain, stroke and multiple sclerosis; Pharmaceutical preparations for the treatment of pain namely neuropathic pain, inflammatory-related pain and fibromyalgia; Pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, COPD, asthma, atherosclerosis, vasculitis, synovitis, psoriasis, eczema, scleroderma, and other inflammatory-related skin disorders; Pharmaceutical preparations for the treatment of blood-related diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, and infections in or of the blood; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders, and injuries, namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, sports injuries, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement, and osteoarthritis; Pharmaceutical preparations for use in ophthalmology; Pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and skin structure diseases, infections, and injuries, psoriasis, eczema, and sexually transmitted diseases; Pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely pre-term labour, hypogonadism, testosterone/androgen disorders and estrogen disorders; Pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders namely irritable bowel disorders and symptoms, digestive disorders, and acid-related disorders; Pharmaceutical preparations for the treatment of sexual dysfunction namely erectile dysfunction, male and females sexual dysfunction disorders namely arousal disorder, pain disorder, desire disorder, and orgasm disorder; Pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders; Pharmaceutical preparations for the treatment of gynaecological diseases, reproductive health and fertility, contraception, bladder and continence disorders, prostate diseases and disorders; Pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, pre-term labour, pre-eclampsia, vasomotor/menopausal symptoms, endometriosis/uterine fibroids, Leiomyoma, endourology/stone; Pharmaceutical preparations for the treatment of infectious diseases namely prostatitis, nephritis, cystitis, vaginitis, STDs; renal disease; Pharmaceutical preparations for the treatment of PMDD/PMS, dysmenorrhea, male hypogonadism, and hormonal disorders namely polycystic ovary syndrome; Pharmaceutical preparations for the treatment of male pattern baldness; Pharmaceutical preparations for the treatment of hepatological related diseases namely hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, and cirrhosis; Pharmaceutical preparations for the treatment of obesity or to aid in weight loss or weight management; Pharmaceutical preparations for the treatment of sepsis; Pharmaceutical preparations for the treatment of alopecia; Pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; Pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely immunosuppressants; Pharmaceutical preparations for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of immunologic diseases and disorders, namely, autoimmune diseases and disorders; Pharmaceutical preparations for the treatment of malaria; Pharmaceutical preparations for the treatment of tuberculosis; Allergy medications; Vaccines namely, prophylactic and therapeutic vaccines for humans.
Classification data
Disclaimer
The classification data is provided for information and searching purposes only. CIPO does not warrant the accuracy of the classes assigned to the trademark. This data has no legal value of any kind.
- 5 - Pharmaceuticals and herbicides
Claims
- Priority Filing Date: May 16, 2008, Country or Office: UNITED KINGDOM, Application No. 2487837 in association with the same kind of goods
- Proposed Use in CANADA
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2008-07-11 | ||
| Created | 2008-07-11 | ||
| Formalized | 2008-07-15 | ||
| Correspondence Created | 2008-08-11 | ||
| Note to file | 2008-09-15 | Amendment recorded as per correspondence dated 20/08/08 | |
| Search Recorded | 2009-05-07 | ||
| Approval Notice Sent | 2009-05-07 | 2009-06-04 | |
| Approved | 2009-06-25 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2009-07-01 | Vol.56 Issue 2853 | |
| Allowed | 2009-10-16 | ||
| Allowance Notice Sent | 2009-10-16 | 2011-07-11 | |
| Extension of Time | 2011-05-12 | 2012-01-11 | Online Request Date: 2011/05/12 |
| Extension of Time | 2011-11-17 | 2012-07-11 | Online Request Date: 2011/11/17 |
| Extension of Time | 2012-06-28 | 2013-01-11 | Online Request Date: 2012/06/28 |
| Extension of Time | 2012-12-11 | 2013-07-11 | Online Request Date: 2012/12/11 |
| Extension of Time | 2013-07-17 | 2014-01-11 | Request Letter Date: 2013/07/11 |
| Amendment to Application | 2013-09-24 | Owner Address Change / Voir Preuve au dossier/See evidence on File No. 62635 | |
| Extension of Time | 2014-01-16 | 2014-07-11 | Request Letter Date: 2014/01/10 |
| Correspondence Created | 2014-07-24 | 2014-09-24 | |
| Abandoned - Subsection 40(3) | 2014-10-15 |